Northern Trust Corp Has $1.76 Million Position in Pharvaris (NASDAQ:PHVS)

Northern Trust Corp increased its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 483.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,932 shares of the company's stock after acquiring an additional 76,188 shares during the quarter. Northern Trust Corp owned about 0.18% of Pharvaris worth $1,762,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Legal & General Group Plc lifted its stake in Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after buying an additional 994 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pharvaris by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after buying an additional 1,356 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Pharvaris in the fourth quarter valued at approximately $111,000. Finally, Palumbo Wealth Management LLC bought a new position in Pharvaris in the fourth quarter valued at approximately $196,000.

Pharvaris Trading Up 8.2%

Shares of NASDAQ PHVS traded up $1.26 during midday trading on Thursday, reaching $16.72. The company's stock had a trading volume of 113,365 shares, compared to its average volume of 72,984. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50. The stock has a market capitalization of $874.29 million, a price-to-earnings ratio of -5.97 and a beta of -2.85. The stock has a 50 day simple moving average of $15.40 and a 200-day simple moving average of $17.26.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). As a group, equities analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

Analysts Set New Price Targets

PHVS has been the topic of a number of research reports. Cantor Fitzgerald cut their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. JMP Securities lifted their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.